All In Biotech

Drug Trial Radar · NCT01869725

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Comparator Study of 68Ga-DOTATOC PET/CT With Octreoscan + High-resolution, Contrast-enhanced CT for Diagnosis and Staging in Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors

Last checked: Nov 20, 2026Latest source record: Sep 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

68

Actual

Start

Apr 1, 2013

Primary completion

Dec 26, 2018

Study completion Dec 26, 2018

Sponsor

Lead sponsor
Sue O'DorisioAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jun 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other somatostatin receptor positive tumors. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT, may help find and diagnose somatostatin receptor positive neuroendocrine tumors. It is not yet known whether Ga 68-edotreotide PET/CT is as effective as indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosis and staging of patients with neuroendocrine tumors.

Conditions

  • Adult Medulloblastoma
  • Childhood Medulloblastoma
  • Neuroblastoma
  • Neuroendocrine Tumor
  • Somatostatinoma

Interventions

  • gallium Ga 68-edotreotideDrug

    Given IV

  • positron emission tomography/computed tomographyProcedure

    Undergo gallium Ga 68-edotreotide PET/CT scan

  • indium In 111 pentetreotideRadiation

    Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan

  • computed tomographyProcedure

    Undergo indium In 111 pentetreotide contrast-enhanced CT scan

  • contrast-enhanced magnetic resonance imagingProcedure

    Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of Conventional Imaging and Gallium Ga 68-edotreotide PET Using Concordance in Tumor Detection With PathologyTime frame: Up to 6 months between the timing of the Octreoscan SPECT/CT plus high-resolution, contrast-enhanced CT and the time of the 68Ga-DOTATOC PET/CT (either imaging type may occur first)
  2. Compare Sensitivity of 68Ga-DOTATOC PET/CT With OctreoscanTime frame: Up to 6 months
  3. Compare Specificity of 68Ga-DOTATOC PET/CT With OctreoscanTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.